ATEA PHARMACEUTIC.DL-,001

Atea Pharmaceuticals has started a randomized, double‑blind, placebo‑controlled phase‑1 study of the oral nucleotide analogue AT‑587 to assess safety, tolerability and pharmacokinetics in healthy volunteers. The study includes single‑ and multiple‑dose parts as well as a food‑effect investigation; dose selection in part B will be based on data from part A. AT‑587 is aimed at chronic HEV infections in immunocompromised patients; in vitro data show greater potency versus sofosbuvir and ribavirin, and the company reports a strong liquidity position. » Mere på de.investing.com

Atea reports progress in the global phase-3 program for BEM/RZR in hepatitis C with recruitment completed in C-BEYOND and C-FORWARD nearly finished; topline results are expected mid- and late-2026 respectively, and a regulatory submission is planned for Q1 2027. The company is adding a preclinical hepatitis E program with AT-587, targeting a phase-1 start by mid-2026 and proof-of-concept in H2 2026. In the Q1 report Atea posted a net loss of USD 45.4m (EPS -0.57), had USD 256m cash as of March 31, 2026, and sees funding secured through the end of 2027. Remaining risks include regulatory competition and possible study delays. » Mere på de.investing.com

Atea reported Q4 and full-year 2025 results and announced progress in its antiviral pipeline, including the phase-3 program for the fixed-dose combination bemnifosbuvir/ruzasvir (BEM/RZR). Recruitment for the C-BEYOND study is complete; initial phase-3 results are expected in mid-2026, with C-FORWARD planned for mid to late 2026. Atea holds $301.8 million in cash, giving it a liquidity runway through the end of 2027; the company also plans to start phase 1 development of AT-587 for HEV in mid-2026. Despite missing EPS, investors reacted positively to the upcoming clinical milestones and the commercial potential of BEM/RZR. » Mere på de.investing.com